Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas

British Journal of Dermatology

Volumn 173, Issue 2, 2015, Pages 527-534

  Reigneau, M ^a   Robert, C ^a   Routier, E ^a   Mamelle, G ^a   Moya Plana, A ^a   Tomasic, G ^a   Mateus, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CARDIOPULMONARY INSUFFICIENCY; CAUSE OF DEATH; CLINICAL ARTICLE; DISTANT METASTASIS; DRUG EFFICACY; FEMALE; FOLLICULITIS; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LUNG INFECTION; MALE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON MELANOMA SKIN CANCER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; SKIN NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; FOLLICULITIS; HUMANS; MALE; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84941175464     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13741     Document Type: Article

References (18)

1. Alam M, Ratner D,. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344: 975-83.
2. Sadek H, Azli N, Wendling JL, et al,. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990; 66: 1692-6.
3. Khansur T, Kennedy A,. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 1991; 67: 2030-2.
4. Vermorken JB, Mesia R, Rivera F, et al,. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.
5. Bourhis J, Rivera F, Mesia R, et al,. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-72.
6. Licitra L, Mesia R, Rivera F, et al,. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011; 22: 1078-87.
7. Herbst RS, Arquette M, Shin DM, et al,. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-87.
8. Maubec E, Petrow P, Scheer-Senyarich I, et al,. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419-26.
9. Giacchero D, Barrière J, Benezery K, et al,. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma-a report of eight cases. Clin Oncol 2011; 23: 716-18.
10. Suen JK, Bressler L, Shord SS, et al,. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007; 18: 827-9.
11. Bauman JE, Eaton KD, Martins RG,. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007; 143: 889-92.
12. Kim S, Eleff M, Nicolaou N,. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck 2011; 33: 286-8.
13. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH,. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009; 219: 80-3.
14. Preneau S, Rio E, Brocard A, et al,. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 2014; 25: 424-7.
15. Kalapurakal SJ, Malone J, Robbins KT, et al,. Cetuximab in refractory skin cancer treatment. J Cancer 2012; 3: 257-61.
16. Lewis CM, Glisson BS, Feng L, et al,. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18: 1435-46.
17. Cunningham D, Humblet Y, Siena S, et al,. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
18. Bonner JA, Harari PM, Giralt J, et al,. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.